Asset Details
Do you wish to reserve the book?
Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update
Do you wish to request the book?
Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update
2018
Overview
Despite the excellent efficacy and improved clinical responses obtained with imatinib mesylate (IM), development of resistance in a significant proportion of chronic myeloid leukemia (CML) patients on IM therapy have emerged as a challenging problem in clinical practice. Resistance to imatinib can be due to heterogeneous array of factors involving BCR/ABL-dependent and BCR/ABL-independent pathways. Although BCR/ABL mutation is the major contributory factor for IM resistance, reduced bio-availability of IM in leukemic cells is also an important pharmacokinetic factor that contributes to development of resistance to IM in CML patients. The contribution of polymorphisms of the pharmacogenes in relation to IM disposition and treatment outcomes have been studied by various research groups in numerous population cohorts. However, the conclusions arising from these studies have been highly inconsistent. This review encompasses an updated insight into the impact of pharmacogenetic variability on treatment response of IM in CML patients.
Publisher
Future Medicine Ltd
Subject
Antineoplastic Agents - therapeutic use
/ Disease
/ Drug Resistance, Neoplasm - genetics
/ Drugs
/ Genes
/ Genomes
/ Genomics
/ Humans
/ Imatinib
/ Imatinib Mesylate - therapeutic use
/ Kinases
/ Leukemia
/ Leukemia, Myeloid, Acute - drug therapy
/ Leukemia, Myeloid, Acute - genetics
/ Patients
/ Polymorphism, Single Nucleotide - genetics
/ Protein Kinase Inhibitors - therapeutic use
/ response
/ SNPs
